Security
Enliven Therapeutics, Inc. Common Stock · ELVN
ELVNNASDAQCommon stockCurrentCIK 1672619Updated Oct 3, 2026
Name history
IMARA Inc. · through Feb 23, 2023
ELVN price & chart
Loading TradingView…
NASDAQ:ELVN on TradingView ↗About the company
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.
In the news
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update News provided by Enliven Therapeutics, Inc. Aug 13, 2025, 16:05 ET Share this article Share to X Share this article Share to X Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, repo ↗
Recent filings
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
144 filing
4 filing
144 filing
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 476,168,000Source | 325,760,000Source | 271,867,000Source | 91,959,000Source |
| Property, Plant and Equipment, NetUSD | 34,000Source | 458,000Source | 742,000Source | 890,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 98,896,000Source | 124,117,000Source | 100,141,000Source | 88,198,000Source |
| Assets, CurrentUSD | 474,878,000Source | 318,127,000Source | 266,151,000Source | 89,636,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 12,257,000Source | 4,633,000Source | 2,949,000Source | 1,438,000Source |
| Operating Lease, Right-of-Use AssetUSD | 383,000Source | 0Source | 320,000Source | — |
| Other Assets, NoncurrentUSD | 656,000Source | 7,175,000Source | 4,091,000Source | 2,323,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 16,568,000Source | 15,915,000Source | 25,961,000Source | 1,830,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 59,000Source | 49,000Source | 41,000Source | 27,000Source |
| Additional Paid in CapitalUSD | 806,373,000Source | 553,213,000Source | 400,172,000Source | 236,111,000Source |
| Retained Earnings (Accumulated Deficit)USD | -347,166,000Source | -243,472,000Source | -154,448,000Source | -146,009,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 334,000Source | 55,000Source | 141,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 459,600,000Source | 309,845,000Source | 245,906,000Source | 90,129,000Source |
| Liabilities and EquityUSD | 476,168,000Source | 325,760,000Source | 271,867,000Source | 91,959,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 16,568,000Source | 15,915,000Source | 25,894,000Source | 1,830,000Source |
| Operating Lease, Liability, CurrentUSD | 399,000Source | — | 335,000Source | — |
| Accounts Payable, CurrentUSD | 2,159,000Source | 1,342,000Source | 532,000Source | 149,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | — | 0Source | — |
| Other Liabilities, NoncurrentUSD | — | 0Source | 67,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | — | 1,681,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 462,600,000Source | 313,400,000Source | 253,100,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 300,000Source | 300,000Source | 300,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 34,019,000Source | 20,174,000Source | 12,914,000Source | 2,595,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 817,000Source | 810,000Source | -2,250,000Source | -2,213,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -70,301,000Source | -73,192,000Source | -61,269,000Source | -35,568,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -173,841,000Source | -35,997,000Source | -148,412,000Source | 76,515,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 218,867,000Source | 133,165,000Source | 234,286,000Source | -1,233,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 98,896,000Source | 124,171,000Source | 100,195,000Source | 88,198,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 34,019,000Source | 20,174,000Source | 12,914,000Source | 2,595,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 462,600,000Source | 313,400,000Source | 253,100,000Source | — |
| DepreciationUSD | 263,000Source | 317,000Source | 297,000Source | 611,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | -106,000Source | -11,000Source | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | 35,000,000Source |
| General and Administrative ExpenseUSD | 33,802,000Source | 23,776,000Source | 18,955,000Source | 15,330,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 232,000Source | 0Source | 88,000Source |
| Net Income (Loss) Attributable to ParentUSD | -103,694,000Source | -89,024,000Source | -71,584,000Source | 1,488,000Source |
| Nonoperating Income (Expense)USD | 15,964,000Source | 15,530,000Source | 11,945,000Source | 846,000Source |
| Operating ExpensesUSD | 119,658,000Source | 104,554,000Source | 83,529,000Source | 34,270,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 500,000Source |
| Operating Lease, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Other Nonoperating Income (Expense)USD | -49,000Source | -2,000Source | -22,000Source | -97,000Source |
| Proceeds from Issuance of Common StockUSD | — | 0Source | 161,365,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 2,295,000Source | 3,631,000Source | 399,000Source | — |
| Realized Investment Gains (Losses)USD | — | — | — | 16,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -119,658,000Source | -104,554,000Source | -83,529,000Source | 730,000Source |
| Other Nonoperating Income (Expense)USD | -49,000Source | -2,000Source | -22,000Source | -97,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | 1,576,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 232,000Source | 0Source | 88,000Source |
| Net Income (Loss) Attributable to ParentUSD | -103,694,000Source | -89,024,000Source | -71,584,000Source | 1,488,000Source |
| Earnings Per Share, BasicUSD per share | -1.83Source | -1.89Source | -2.01Source | 0.06Source |
| Earnings Per Share, DilutedUSD per share | -1.83Source | -1.89Source | -2.01Source | 0.06Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 56,664,226Source | 47,072,532Source | 35,546,215Source | 26,287,264Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 56,664,226Source | 47,072,532Source | 35,546,215Source | 26,385,567Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 33,802,000Source | 23,776,000Source | 18,955,000Source | 15,330,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 16,013,000Source | 14,891,000Source | 11,967,000Source | 943,000Source |
| Nonoperating Income (Expense)USD | 15,964,000Source | 15,530,000Source | 11,945,000Source | 846,000Source |
| Operating ExpensesUSD | 119,658,000Source | 104,554,000Source | 83,529,000Source | 34,270,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 500,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | 16,000Source |
| Research and Development ExpenseUSD | 85,856,000Source | 80,778,000Source | 64,574,000Source | 18,940,000Source |
Filing attachments
elvn-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 elvn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignment with the FDA on key Phase 3 trial design components Strong balance sheet with $895 million in cash, cash equivalents and marketable securities, which is expected to p…
Read attachment ↗d152122dex41.htm · 8-K · 2026-06-12
EX-4.1 3 d152122dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [___] Original Issue Date: [ ], 2026 ENLIVEN THERAPEUTICS, INC. Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subj…
Read attachment ↗d152122dex991.htm · 8-K · 2026-06-12
EX-99.1 5 d152122dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants BURLINGAME, CA, June 11, 2026 /PRNewswire/ - Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8…
Read attachment ↗d202685dex991.htm · 8-K · 2026-06-11
EX-99.1 2 d202685dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components 61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prior unique TKIs Favorable safety and tolerability profile with 161 patients enrolled and a median treatm…
Read attachment ↗elvn-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 elvn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029 BOULDER, Colo., May 7, 2026 /PRNew…
Read attachment ↗elvn-ex99_1.htm · 8-K · 2026-03-03
EX-99.1 2 elvn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Key data readout, regulatory interactions, and operational catalysts throughout 2026 Strong balance sheet with $463 million in cash, cash equivalents and marketable s…
Read attachment ↗